TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of speech performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow redistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective memory complaints
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EuroQol- 5 Dimension- 5 Level (EQ-5D-5L) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thickness of the retina and retinal nerve fiber layer (RNFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety assessed by Children's State Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear by Children's Fear Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in fasting high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-rated global health improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of Non-Medical Use of a Prescription Opioid
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive impairment evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Alglucosidase Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alglucosidase Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) of Alglucosidase Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Pressure Pain Threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative delirium incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Penile circumference increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment with ZK-Epo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-Organ Magnetic Resonance Imaging Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very late use of the HIV test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics/pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estrogenic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 72-hour serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IL1RAP protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodily Pain Standardized Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasmatic concentrations of sévoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of binge episodes/days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Late-Onset Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression-Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility to Mobilize and Infuse Autologous Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in total score of the Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum matrix metalloproteinase-14 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPADE symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Physical function NRS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with Adequate High-Quality Brachytherapy Implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Melasma Area and Severity Index (MASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reversal of renal lipotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ambulatory Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of post operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet sequestration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total hand hygiene compliance of health care workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Health care associated infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: P. vivax parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Optimal Dose of Calcineurin Inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Risk Factors for Cardiovascular Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant tissue response to transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of Fluzoparib in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative analysis of whole radioactivity of excrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observation of safety following administration
Endpoint domain: Adverse events/effects
Primary endpoint: Average exhaled title volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Strabismus occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of plasma glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute change in mean daily plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak FEV1 (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wrinkle reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Greater Than or Equal to (>=)15 Letters From the Baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Minnesota Low-vision Reading (MNRead) Test at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arginolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline concentration of endocannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fibrous cap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aldehyde Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overground gait walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overground gait step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity spasticity as measured by the Modified Tardieu Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute pain after implant surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Scale-17 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montgomery-Asberg Depression Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overactive bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: awake time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in plasma soluble CD14 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Endopat measure of microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in target to background ratio measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative cognitive decline at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative cognitive decline at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative delirium in ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative delirium on normal ward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Length of Hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of life measured by the Oswestry Disability Index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wheal size of the immediate reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement surface of the center of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of the displacement of the center of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of rebalancing gestures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 61
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of All Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 61
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive function as measured by ADAS-cog/11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Depression and Anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Baseline general quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Baseline Physical stress level and cortisol rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in hospital costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Kinematic Gait Parameters at Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Cesarean pain scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Assigned
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic performance of copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knowledge and attitude toward PPE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk Adjusted Complications and Death Composite Measure
Endpoint domain: Mortality/survival
Primary endpoint: Survival of patients at 12 months postoperatively
Endpoint domain: Mortality/survival
Primary endpoint: incretin effect after an oral glucose challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in fluoride concentration in enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fluoride concentration in dental biofilm fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who are eligible for the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible women who enroll in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of enrolled women who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Penile elastography measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Administered Dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PRTEE (Patient Rated Tennis Elbow Evaluation)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: apoptosis rate in HUVEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on the Visual Analogue Scale for Leg Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of dysglicemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total load of PJS-related intestinal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline Parenting Survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial-dependent vasorelaxation (EDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial-independent vasorelaxation (EIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient compliance rate of metabolic evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: patient compliance rate of dietary suggestions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: patient compliance rate of drug treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patterns of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Closure of Target Vein(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Spontaneous Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline 'Fugl-Meyer Assessment of the Upper Extremity (FMA-UE)'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Drug Cue Reactivity BOLD Signal in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drug Cue Reactivity Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbial culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraoperative serum cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Successful placement of Balt Goldbal2 balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful removal of Balt Goldbal2 balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Graft Failure
Endpoint domain: Mortality/survival
Primary endpoint: maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to relapse of iron deficiency anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area of incisional secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Accuracy on High-control Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control-related BOLD Signal Change in Locus Coeruleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gamma Power Change in Count of Clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG Slow Wave Activity During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime Sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Variation in sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: number of items completed of ERAS protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: degree of adaptability
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reticulocyte hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immature reticulocyte fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of Keishibukuryogan
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Rate (PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with respiratory morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lymphocyte Subtest of Complete Blood Count Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects with sizing procedure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of a combined investigational device safety endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: mean postoperative pain (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five times Sit to Stand test (5STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symbol Digit Modalities Test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Average Change in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of substance use disorders with zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the 6 minute walk test (6mWT) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Atherosclerotic burden and lesion complexity on angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of OSI-774
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: incidence of glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Completeness of biofilm removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Eating Disorder Examination-Questionnaire (EDE-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Decay Half-Life (t1/2) of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal intimal-medial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes